

Message

From: Ross Wilson [Ex. 6 Personal Privacy (PP)]
Sent: 2/2/2017 12:39:33 AM
To: Newhouse, Kathleen [Newhouse.Kathleen@epa.gov]
Subject: RE: benzo[a]pyrene

Thanks very much for the information, Kathleen. Very useful!

Ross Wilson, M.Sc., DABT
[Ex. 6 Personal Privacy (PP)]

From: Newhouse, Kathleen [mailto:Newhouse.Kathleen@epa.gov]
Sent: Wednesday, February 1, 2017 3:45 PM
To: Ross Wilson <[Ex. 6 Personal Privacy (PP)]>
Subject: RE: benzo[a]pyrene

Hi Ross,

Regarding noncancer risks: While it is possible that some of the other PAHs may have similar noncancer effects, the BaP assessment is an assessment of the effects of BaP alone, so it would not be scientifically supportable to use the BaP noncancer toxicity values to stand in for other PAHs.

Regarding cancer risks: It is appropriate to apply the newly released BaP oral slope factor and inhalation unit risk to estimate cancer risk of PAH mixtures using the relative potency factors (RPFs) provided in the 1993 guidance (<https://cfpub.epa.gov/ncea/risk/recordisplay.cfm?deid=49732>). Please bear in mind that the RPFs are for cancer risk only, and are not applicable to non-cancer endpoints. We are continuing to revise the External Peer Review draft PAH RPF Approach (https://cfpub.epa.gov/ncea/iris_drafts/recordisplay.cfm?deid=194584), but no further information on timing is currently available. For the latest information, please keep an eye on the IRIS website (<https://www.epa.gov/iris>).

-Kathleen

From: Ross Wilson [Ex. 6 Personal Privacy (PP)]
Sent: Monday, January 30, 2017 12:41 PM
To: Newhouse, Kathleen <Newhouse.Kathleen@epa.gov>
Subject: benzo[a]pyrene

Kathleen

Congratulations on US EPA's new document on benzo[a]pyrene. It looks very impressive! Two questions:

- For evaluation of non-cancer risks, does US EPA have any suggestion on how to evaluate non-cancer risks to the other PAHs? For example, would US EPA recommend using the RfD or RFC for benzo[a]pyrene to evaluate the non-cancer risk to chrysene?
- For evaluation of cancer risks, does US EPA have recommended potency equivalency factors for the other PAHs.

Thanks for any information you may be able to share.

Ross Wilson, M.Sc., DABT

Wilson Scientific Consulting Inc.

Ex. 6 Personal Privacy (PP)

Telephone: Ex. 6 Personal Privacy (PP)

Cell phone: Ex. 6 Personal Privacy (PP)

Email: Ex. 5 Deliberative Process (DP)